Thomas Knoepfel

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 6

Top Venues

Journal of medicinal chemistry

ACS medicinal chemistry letters

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Juraj Velcicky, Matthias R Bauer, Achim Schlapbach, Guillaume Lapointe, Arndt Meyer, Markus Vögtle, Ernst Blum, Estelle Ngo, Catherine Rolando, Pierre Nimsgern, Sylvie Teixeira-Fouchard, Hansjoerg Lehmann, Pascal Furet, Frédéric Berst, Jens Schümann, Rowan Stringer, Patrice Larger, Cindy Schmid, Catriona T Prendergast, Simone Riek, Patrick Schmutz, Sylvie Lehmann, Jörg Berghausen, Clemens Scheufler, Jean-Michel Rondeau, Christoph Burkhart, Thomas Knoepfel, Nina Gommermann
Discovery and In Vivo Exploration of 1,3,4-Oxadiazole and α-Fluoroacrylate Containing IL-17 Inhibitors. Journal of medicinal chemistry (2024)
Phil B Alper, Claudia Betschart, Cédric André, Thomas Boulay, Dai Cheng, Jonathan Deane, Michael Faller, Roland Feifel, Ralf Glatthar, Dong Han, Rene Hemmig, Tao Jiang, Thomas Knoepfel, Jillian Maginnis, Daniel Mutnick, Wei Pei, Giulia Ruzzante, Peter Syka, Guobao Zhang, Yi Zhang, Florence Zink, Géraldine Zipfel, Stuart Hawtin, Tobias Junt, Pierre-Yves Michellys
Discovery of the TLR7/8 Antagonist MHV370 for Treatment of Systemic Autoimmune Diseases. ACS medicinal chemistry letters 14 (8) (2023)
Claudia Betschart, Michael Faller, Florence Zink, René Hemmig, Jutta Blank, Eric Vangrevelinghe, Marjorie Bourrel, Ralf Glatthar, Dirk Behnke, Kerstin Barker, Andreas Heizmann, Daniela Angst, Pierre Nimsgern, Sébastien Jacquier, Tobias Junt, Géraldine Zipfel, Giulia Ruzzante, Pius Loetscher, Sarah Limonta, Stuart Hawtin, Cedric Bernard Andre, Thomas Boulay, Roland Feifel, Thomas Knoepfel
Structure-Based Optimization of a Fragment-like TLR8 Binding Screening Hit to an In Vivo Efficacious TLR7/8 Antagonist. ACS medicinal chemistry letters 13 (4) (2022)
Thomas Knoepfel, Pierre Nimsgern, Sébastien Jacquier, Marjorie Bourrel, Eric Vangrevelinghe, Ralf Glatthar, Dirk Behnke, Phil B Alper, Pierre-Yves Michellys, Jonathan Deane, Tobias Junt, Géraldine Zipfel, Sarah Limonta, Stuart Hawtin, Cedric Andre, Thomas Boulay, Pius Loetscher, Michael Faller, Jutta Blank, Roland Feifel, Claudia Betschart
Target-Based Identification and Optimization of 5-Indazol-5-yl Pyridones as Toll-like Receptor 7 and 8 Antagonists Using a Biochemical TLR8 Antagonist Competition Assay. Journal of medicinal chemistry 63 (15) (2020)
Robin A Fairhurst, Thomas Knoepfel, Nicole Buschmann, Catherine Leblanc, Robert Mah, Milen Todorov, Pierre Nimsgern, Sebastien Ripoche, Michel Niklaus, Nicolas Warin, Van Huy Luu, Mario Madoerin, Jasmin Wirth, Diana Graus-Porta, Andreas Weiss, Michael Kiffe, Markus Wartmann, Jacqueline Kinyamu-Akunda, Dario Sterker, Christelle Stamm, Flavia Adler, Alexandra Buhles, Heiko Schadt, Philippe Couttet, Jutta Blank, Inga Galuba, Jörg Trappe, Johannes Voshol, Nils Ostermann, Chao Zou, Jörg Berghausen, Alberto Del Rio Espinola, Wolfgang Jahnke, Pascal Furet
Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4. Journal of medicinal chemistry 63 (21) (2020)
Andreas Weiss, Flavia Adler, Alexandra Buhles, Christelle Stamm, Robin A Fairhurst, Michael Kiffe, Dario Sterker, Mario Centeleghe, Markus Wartmann, Jacqueline Kinyamu-Akunda, Heiko S Schadt, Philippe Couttet, Armin Wolf, Youzhen Wang, Patrizia Barzaghi-Rinaudo, Masato Murakami, Audrey Kauffmann, Thomas Knoepfel, Nicole Buschmann, Catherine Leblanc, Robert Mah, Pascal Furet, Jutta Blank, Francesco Hofmann, William R Sellers, Diana Graus Porta
FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer. Molecular cancer therapeutics 18 (12) (2019)

Thomas Knoepfel.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Thomas Knoepfel